Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:20 PM
Ignite Modification Date:
2025-12-24 @ 10:20 PM
NCT ID:
NCT00904735
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosed with meningioma
* WHO grade I-III
* Recurrent or progressive disease after prior surgery and radiotherapy, or radiosurgery
* Not amenable to further surgery
* No optic nerve sheet tumor and neurofibromatosis type II
* No known brain metastasis
PATIENT CHARACTERISTICS:
* WHO performance status 0-2
* ANC \> 1,500/mm\^3
* Platelet count \> 100,000/mm\^3
* Hemoglobin ≥ 9 mg/dL (transfusion allowed)
* Total bilirubin \< 1.5 times upper limit of normal (ULN)
* SGOT and SGPT \< 2.5 times ULN
* Creatinine \< 1.5 times ULN
* Negative pregnancy test
* Fertile patients must use effective barrier method contraception during and for up to 3 months after completion of study therapy
* No second malignancy
* No known chronic liver disease (i.e., active hepatitis, cirrhosis)
* No known HIV infection
* No significant history of non-compliance to medical regimens or inability to grant reliable informed consent
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No concurrent enzyme-inducing anti-epileptic drugs
* No concurrent therapeutic anticoagulation with warfarin (e.g., Coumadin®)
* Low-molecular weight heparin (e.g., Lovenox) or heparin allowed
* Mini-dose Coumadin® (e.g., 1 mg QD) allowed for prophylaxis of central venous catheter thrombosis, at the discretion of the treating physician
* No concurrent acetaminophen (Efferalgan®, Tachipirina®) allowed during imatinib mesylate administration
* No other concurrent anticancer agents, including chemotherapy or biological agents
* No other concurrent investigational drugs
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT00904735
Study Brief:
Protocol Section:
NCT00904735